Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of the claims in the application:

Listing of Claims

1. (currently amended) ~~Use~~ A method of treating a patient undergoing treatment with an immunosuppressant comprising a step of administering to the patient a therapeutically effective dose of a protective oligodeoxyribonucleotide ~~for the manufacture of a medicament for the treatment of a patient undergoing~~ and achieving a reduction in complications related to treatment with an immunosuppressant.

2. (currently amended) ~~Use~~ A method of treating a patient undergoing treatment with an immunosuppressant comprising a step of administering to the patient a therapeutically effective dose of a protective oligodeoxyribonucleotide ~~for the manufacture of a medicament for protecting~~ and achieving protection of one or both of the patient's epithelial ~~and/~~ or endothelial cells from the effects of ~~an~~ the immunosuppressant.

3. (currently amended) ~~Use~~ A method of treating a patient undergoing treatment with an immunosuppressant comprising a step of administering to the patient a therapeutically effective dose of a protective oligodeoxyribonucleotide for ~~the manufacture of a medicament for protecting~~ and achieving protection one or both of the patient's epithelial ~~and/~~ or endothelial cells from one or both of apoptosis ~~and/~~ or activation induced by the administration of ~~an~~ the immunosuppressant.

4. (currently amended) ~~Use~~ The method according to claim 1 wherein the immunosuppressant is a nucleoside.

5. (currently amended) ~~Use~~ The method according to claim 1 wherein the immunosuppressant is ~~selected~~ chosen from the group comprising 5-fluorouracil, methotrexate, fludarabine, vincristine, vinblastine, paclitaxel, docetaxel, cyclophosphamide, ~~BCNU~~ bischloroethylnitrosurea, melphalan, cisplatin, carboplatin, oxaliplatin, JM-216, Ci-973, doxorubicin, daunorubicin, mitomycin-C, etoposide, camptothecin, cyclosporin, tacrolimus, sirolimus, or combinations thereof.

6. (previously cancelled)

7. (currently amended) ~~Use~~ The method according to claim 1 wherein the protective oligodeoxyribonucleotide is defibrotide.

8. (currently amended) ~~Use~~ The method according to claim 1 wherein the step of administering the protective oligodeoxyribonucleotide occurs as one or more of concurrently with, concomitantly with, simultaneously with, after, or before the administration of the immunosuppressant to the patient.

9. (currently amended) ~~Use~~ The method according to claim 1wherein the step of administering the protective oligodeoxyribonucleotide occurs after that of administering the immunosuppressant to the patient.

10. (currently amended) ~~Use~~ The method according to claim 9 wherein the time delay between the step of administering the protective oligodeoxyribonucleotide and that of administering the immunosuppressant to the patient is from about one hour to about two weeks.

11. (currently amended) ~~Use~~ The method according to claim 1wherein the step of administering the protective oligodeoxyribonucleotide occurs before that of administering the immunosuppressant to the patient.

12. (currently amended) ~~Use~~ The method according to claim 11 wherein the time difference between the step of administering the protective oligodeoxyribonucleotide and that of administering the immunosuppressant to the patient is from about one hour to about two weeks.

13. (currently amended) ~~Use~~ The method according to claim 7 wherein the dose of the defibrotide administered is chosen so as to reach a blood level in the patient from about 100 μg/mL to about 0.1 μg/mL.

14. (currently amended) ~~Use~~ The method according to claim 13 wherein the dose of defibrotide administered is chosen so as to reach a blood level in the patient of about 10 µg/mL.

15. (currently amended) ~~Use~~ The method according claim 7 wherein the dose of defibrotide administered is from about 100 mg/kg body weight of the patient to about 0.01 mg/kg body weight.

16. (currently amended) ~~Use~~ The method according to claim 15 wherein the dose of defibrotide administered is from about 15 mg/kg body weight of the patient to about 1 mg/kg body weight.

17. (currently amended) ~~Use~~ The method according to claim 3 wherein the activation includes enhanced expression of ICAM-1.

18. (currently amended) ~~Use~~ The method according to claim 1 wherein the treatment with an immunosuppressant occurs during stem cell ~~translation~~ transplantation.

19. (currently amended) ~~Use~~ The method according to claim 18 wherein the stem cell transplantation is allogeneic stem cell transplantation.

20. (original) A pharmaceutical composition containing a therapeutically effective dose of an immunosuppressant and of a protective oligodeoxyribonucleotide.

21. (currently amended) A pharmaceutical composition according to claim 20 constituted by two different separately administrable formulations, one formulation containing the immunosuppressant and the other formulation containing the protective oligodeoxyribonucleotide.

22. (currently amended) A pharmaceutical composition according to claim 20 as a combined preparation for one or more of simultaneous, separate, or sequential administration ~~use~~.

23. (previously amended) A pharmaceutical composition according to claim 20 wherein the

immunosuppressant is a nucleoside.

24. (currently amended) A pharmaceutical composition according to claim 20 wherein the immunosuppressant is ~~selected~~ chosen from the group comprising 5-fluorouracil, methotrexate, fludarabine, vincristine, vinblastine, paclitaxel, docetaxel, cyclophosphamide, ~~BCNU~~ bischloroethylnitrosurea, melphalan, cisplatin, carboplatin, oxaliplatin, JM-216, Ci-973, doxorubicin, daunorubicin, mitomycin-C, etoposide, camptothecin, cyclosporin, tacrolimus, sirolimus, or combinations thereof.

25. (previously cancelled)

26. (previously amended) A pharmaceutical composition according to claim 20 wherein the protective oligodeoxyribonucleotide is defibrotide.

27. (currently amended) A pharmaceutical composition according to claim 20 characterized by further containing one or more of customary excipients ~~and/~~ or adjuvants.

28. (currently amended) A pharmaceutical composition according to claim 20 characterized in that ~~it~~ the composition is intravenously injectable.

29. (currently amended) ~~Use~~ The method according to claim 9 wherein the time delay between the step of administering the protective oligodeoxyribonucleotide and that of administering the immunosuppressant to the patient is from about two days to about seven days.

30. (currently amended) ~~Use~~ The method according to claim 11 wherein the time difference between the step of administering the protective oligodeoxyribonucleotide and that of administering the immunosuppressant to the patient is from about two hours to about two days.

31. (currently amended) ~~Use~~ The method according to claim 7 wherein the dose of the defibrotide administered is chosen so as to reach a blood level in the patient from about 10 μg/mL to about 100 μg/mL.

32. (currently amended) ~~Use~~ The method according claim 7 wherein the dose of defibrotide administered is from about 20 mg/kg weight of the patient to about 0.1 mg/kg body weight.

33. (currently amended) ~~Use~~ The method according claim 32 wherein the dose of defibrotide administered is about 12 mg/kg weight of the patient.

34. (currently amended) A pharmaceutical composition according to claim 20 as a combined preparation for separate ~~use~~ administration.

35. (currently amended) A pharmaceutical composition according to claim 20 as a combined preparation for sequential ~~use~~ administration.

36. (new) The method according to claim 1 wherein the immunosuppressant is chosen from the group comprising antimetabolites, anti-microtubule agents, taxanes, alkylating agents, platinum agents, anthracyclines, antibiotic agents, topoisomerase inhibitors, other cytotoxic agents, or combinations thereof.

37. (new) A pharmaceutical composition according to claim 20 wherein the immunosuppressant is chosen from the group comprising antimetabolites, anti-microtubule agents, taxanes, alkylating agents, platinum agents, anthracyclines, antibiotic agents, topoisomerase inhibitors, other cytotoxic agents, or combinations thereof.

38. (new) The method according to claim 1 wherein the treatment with an immunosuppressant occurs during bone marrow transplantation.